Toklu Yasin, Sarac Ozge, Berk Sule, Simsek Saban
1st Ophthalmology Department, Ankara Atatürk Research and Training Hospital, Bilkent, Ankara, Turkey.
Cutan Ocul Toxicol. 2012 Mar;31(1):85-6. doi: 10.3109/15569527.2011.609207.
A 47-year-old male with a history of diabetes mellitus type 2 exhibited with decreased vision in both eyes. The diagnosis of cystoid macular edema (CME) was made and it was decided to administer bilateral intravitreal bevacizumab (Avastin) injections. After intravitreal bevacizumab injection (1.25 mg/0.05 cc) to the right eye the patient had angioedema and conjunctival chemosis in the right eye which resolved in 48 h. One month later the left eye received intravitreal bevacizumab injection under the same conditions. Thirty minutes after the injection angioedema and conjunctival chemosis occurred in the left eye in which the signs and symptoms improved in 48 h. This report is the first one which describes angioedema after intravitreal bevacizumab injection. Care should be taken against the systemic hypersensitivity reactions when planned to receive intravitreal bevacizumab injection.
一名47岁的2型糖尿病男性患者出现双眼视力下降。诊断为黄斑囊样水肿（CME），决定给予双眼玻璃体内注射贝伐单抗（阿瓦斯汀）。右眼玻璃体内注射贝伐单抗（1.25mg/0.05cc）后，患者右眼出现血管性水肿和结膜水肿，48小时内消退。1个月后，左眼在相同条件下接受玻璃体内贝伐单抗注射。注射后30分钟，左眼出现血管性水肿和结膜水肿，48小时内症状体征改善。本报告是首例描述玻璃体内注射贝伐单抗后血管性水肿的报告。计划接受玻璃体内贝伐单抗注射时应注意全身性过敏反应。
